Skip to main content

Bispecific Antibodies

In-Depth Treatment Profile, FDA Approvals, Bispecific Antibodies

Epkinly Receives Accelerated Approval for Treatment of Follicular Lymphoma After ≥2 Lines of Systemic Therapy

Rohan Vashi, PharmD, MSc

Rohan Vashi, PharmD, MSc

In-Depth Treatment Profile, A Payer Perspective, FDA Approvals, Bispecific Antibodies

Bispecific Antibody Columvi Offering Option in Diffuse Large B-cell Lymphoma Treatment

Rohan Vashi, PharmD, MSc

Rohan Vashi, PharmD, MSc

In-Depth Treatment Profile, Multiple Myeloma, Oncology, Bispecific Antibodies

Ongoing Analyses and Recent Data for Talvey in Multiple Myeloma

Rohan Vashi, PharmD, MSc

Rohan Vashi, PharmD, MSc

FDA Approvals, Bispecific Antibodies

FDA Accelerated the Approval of Talvey, First Bispecific GPRC5D-Directed CD3 T-Cell Engager, for Relapsed or Refractory MM

Multiple Myeloma, Oncology, Bispecific Antibodies

Bispecific Antibodies in Phase 1 Studies Show Promising Efficacy in Heavily Pretreated Patients with Multiple Myeloma

Wayne Kuznar

Results 1 - 5 of 5